Endtb Endtb Tb Proof

Endtb Endtb Tb Proof This is a phase iii, randomized, controlled, open label, non inferiority, multi country trial evaluating the efficacy and safety of new combination regimens for mdr tb treatment. On 16 july 2025, the lancet respiratory medicine published the results of the phase iii endtb‑q study, the first clinical trial to focus exclusively on pre‑extensively drug‑resistant tuberculosis (pre‑xdr‑tb). after 3 years of preparation, the endtb data is now open for requests!.

A New Partnership To Improve Tb Treatments Around The World Endtb The advent of new drugs to treat tuberculosis and enhanced funding now permit randomized, controlled trials of shortened duration, all oral treatments for rifampin resistant tuberculosis. The endtb clinical trial is a phase iii, randomized, controlled, open label, non inferiority, multi country trial evaluating the efficacy and safety of five new, all oral, shortened 9 month regimens for fluoroquinolone susceptible multidrug resistant tuberculosis (mdr tb). Current guidelines on pre xdr tuberculosis treatment rely on low certainty evidence, partly due to the absence of randomised controlled trials focused exclusively on pre xdr tuberculosis. Treatment of multidrug and rifampin resistant tuberculosis (mdr rr tb) is expensive, labour intensive, and associated with substantial adverse events and poor outcomes.

Endtb Data Currently Available In Edsi Endtb Current guidelines on pre xdr tuberculosis treatment rely on low certainty evidence, partly due to the absence of randomised controlled trials focused exclusively on pre xdr tuberculosis. Treatment of multidrug and rifampin resistant tuberculosis (mdr rr tb) is expensive, labour intensive, and associated with substantial adverse events and poor outcomes. Two randomized controlled trials published in 2022 showed that treatment for multidrug resistant rifampicin resistant tuberculosis (mdr rr tb) can be shortened to only 6 months with successful treatment achieved in 90% of study participants. Endtb is a phase iii, pragmatic, multi country, adaptive, randomized, controlled, parallel, open label clinical trial evaluating the efficacy and safety of shorter treatment regimens containing new drugs for patients with fluoroquinolone susceptible, rifampin resistant tuberculosis. The endtb trial demonstrated that three all oral, shortened duration treatment regimens—lasting only nine months—are as effective as the current standard 18 24 month treatments for rifampin resistant tuberculosis (rr tb). The new england journal of medicine (nejm) has published the results of the endtb clinical trial. this study has helped to discover shorter and more tolerable treatment options for the most difficult to treat forms of tuberculosis.